Phibro Animal Health Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAHC research report →
Range $49 – $49
Price Chart
About the company
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products.
- CEO
- Daniel Bendheim
- IPO
- 2014
- Employees
- 2,605
- HQ
- Teaneck, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a longer-term recovery phase, but it remains below its 200-day average, so the trend has not fully reset. Price is working off the 52-week range from the lower half rather than pressing the highs, which keeps the setup constructive but not yet confirmed.
Street sentiment is cautiously positive, with a Buy consensus and a $47 average target versus a recent close in the mid-30s. Recent changes lean constructive: Morgan Stanley lifted its target to $49, while Citigroup initiated coverage at Neutral, suggesting improving but still mixed conviction.
The earnings profile has been strong, with 7 beats in the last 8 quarters and only one flat print. Next-year EPS is modeled at $3.34 versus $2.51 TTM, so shareholders should watch whether revenue growth and margin discipline can keep translating into another step-up in earnings.
No notable discretionary insider buying or selling. Recent activity is dominated by award-related grants and other non-open-market transactions, which are better read as compensation and vesting mechanics than a directional signal.
Profitability is solid, with a 33.3% gross margin, 12.7% operating margin, and 6.67% net margin. Growth is steady too, with revenue up 6.3% year over year and earnings up 10.8%, while ROE of 28.17% points to efficient capital use.
PAHC looks like a niche animal-health and mineral-nutrition operator with steadier economics than many specialty pharma names. The valuation is not stretched at 12.14x earnings, and the market is paying a modest multiple for a business with mid-single-digit revenue growth and strong cash conversion.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.35B
- P/E
- 14.00
- Fwd P/E
- 9.56
- PEG
- 0.27
- P/S
- 0.94
- P/B
- 3.46
- EV/EBITDA
- 9.08
- Div Yield
- 1.35%
- Gross Margin
- 33.78%
- Op Margin
- 12.99%
- Net Margin
- 6.67%
- ROE
- 27.44%
- ROIC
- 11.73%
Latest fiscal year · YoY change
- Revenue
- $1.52B+17.1%
- Gross Profit
- $511.71M+27.9%
- Op Income
- $198.44M
- Net Income
- $99.72M+106.6%
- EPS
- $2.46+106.7%
- OCF Growth
- -13.9%
- FCF Growth
- -76.4%
- 52W High
- $60.08
- 52W Low
- $28.25
- 50D MA
- $36.56
- 200D MA
- $40.93
- Beta
- 0.42
- RSI (14)
- 38
- Avg Volume
- 231.63K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Phibro started fiscal 2027 with 6% sales growth and 4% adjusted EBITDA growth, while keeping full-year guidance unchanged amid mixed animal-health trends and stronger non-animal-health performance.· November 5, 2026
- Q1 net sales rose 6% to $386.8 million and adjusted EBITDA increased 4% to $64.3 million.
- Animal Health sales grew 3%, but poultry-related softness and a $5.2 million drop in Virginiamycin sales in Brazil weighed on the segment.
- Mineral Nutrition and Performance Products were standout performers, up 17% and 16% respectively on stronger demand and pricing.
- Management left fiscal 2027 guidance unchanged: sales of $1.55 billion to $1.6 billion, adjusted EBITDA of $258 million to $268 million, and adjusted diluted EPS of $3.41 to $3.59.
- Cash generation improved, but management said inventory is still too high and reducing it is a priority this year.
Consolidated net sales were $386.8 million in the first quarter, up $22.9 million or 6% year over year. Net income was $29.5 million, up about 11% from $26.5 million a year ago. Adjusted EBITDA increased 4% to $64.3 million, while adjusted net income rose to $32.4 million. Gross margin was not stated in the call. By segment, Animal Health sales were $293 million, up 3%; Mineral Nutrition sales were $73.6 million, up 17%; and Performance Products sales were $20.2 million, up 16%. For fiscal 2027, Phibro reiterated guidance for net sales of $1.550 billion to $1.6 billion, adjusted EBITDA of $258 million to $268 million, adjusted net income of $140 million to $147 million, and adjusted diluted EPS of $3.41 to $3.59. Management said Q2 revenue growth should outpace EBITDA growth because of easier comparisons and costs shifting from Q1 to Q2.
Dani Bendheim said fiscal 2027 is off to a good start and emphasized that the quarter was achieved against a tough comparison. He highlighted a strategic shift in Mineral Nutrition toward higher-margin areas like plant nutrition, dairy and pet food, where customers value sourcing quality, consistency and technical support. On Animal Health, he described current poultry weakness as a temporary producer-margin issue rather than a demand problem, and said the business should normalize over the fiscal year. He also said the company is not counting on any Brazil Virginiamycin sales in its guidance and remains focused on improving cash conversion and reducing inventory.
Glenn David walked through the quarter’s financial bridge, noting that higher SG&A partly offset gross profit improvement at the operating line. Below operating income, lower interest expense, a swing in foreign currency to a $0.4 million gain from a $2 million loss, and lower tax expense helped lift net income to $29.5 million. He said free cash flow over the last 12 months was $22 million, operating cash flow was $86 million, and capital expenditures were $64 million, with cash and short-term investments at $83 million. He also cited gross leverage of 2.9x on $740 million of total debt and net leverage of 2.6x on $656 million of net debt, and said the company paid a $0.12 per share quarterly dividend totaling $4.9 million.
Analysts focused on Virginiamycin in Brazil, the mix of growth in the MFA portfolio, livestock market conditions, and why guidance was not raised after a better-than-expected quarter. Management said there had been no renewed contact with Brazilian regulators after the election, reiterated that no Brazil Virginiamycin sales are built into guidance, and said any approval would be upside. On the MFA mix, Glenn said Zoetis was a major growth contributor, while legacy performance was roughly flat once Virginiamycin weakness was offset by strong ethanol processing aids. On livestock, Larry Miller said producer margins are under pressure in poultry and swine, but feed costs are easing as corn prices fell from about $5.50 to under $4.5 per bushel, and he outlined expected cattle supply support from Mexican imports and beef-on-dairy animals.
The quarter showed solid top-line and EBITDA growth even against a difficult comparison, with particularly strong momentum in Mineral Nutrition and Performance Products. Management also sounded constructive on the medium-term outlook for higher-margin niches, easing feed costs, and eventual normalization in poultry and broader protein markets.
Animal Health is still dealing with soft poultry demand, producer-margin pressure, and a regulatory overhang in Brazil tied to Virginiamycin. Management also flagged higher inventory than desired, said cash conversion needs to improve, and left guidance unchanged despite the stronger first quarter, which suggests continued caution on the back half of the year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 40.60M
- Float Shares
- 40.30M
of shares held by institutions
217 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PAHC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Michael T. McCaulHouse · TX10 | Sell | Sep 1, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 1, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Aug 30, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Aug 30, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Mar 2, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Mar 4, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Mar 2, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Mar 4, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 14, 21 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Mar 4, 21 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Mar 4, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 3.27M | ▲ 105.98K |
| Blackrock, Inc. | 3.22M | ▼ 34.81K |
| Vanguard Group Inc | 1.54M | ▲ 13.88K |
| State Street Corp | 1.04M | ▲ 5.93K |
| Millennium Management LLC | 936.70K | ▲ 880.88K |
| Vanguard Capital Management LLC | 923.32K | ▲ 32.03K |
| Lord, Abbett & Co. LLC | 653.30K | ▲ 255.59K |
| Geode Capital Management, LLC | 610.08K | ▼ 47.27K |
| Advisors Asset Management, Inc. | 574.88K | ▲ 571.90K |
| Dimensional Fund Advisors LP | 538.51K | ▲ 7.42K |
| Vanguard Portfolio Management LLC | 508.49K | ▲ 18.14K |
| Castleknight Management LP | 461.32K | ▲ 385.43K |
Held by 311 ETFs
Biggest fund positions in PAHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 6, 26 | David Glenn | other | 3,482 |
| Aug 6, 26 | Miller Larry Lee | other | 3,726 |
| Aug 6, 26 | Rodriguez Patrick | other | 1,503 |
| Aug 6, 26 | David Glenn | other | 3,334 |
| Aug 6, 26 | Miller Larry Lee | other | 3,522 |
| Aug 6, 26 | BENDHEIM Jonathan | other | 2,716 |
| Aug 6, 26 | Weinstein Judith | other | 2,478 |
| Aug 6, 26 | BENDHEIM JACK | other | 12,103 |
| Aug 6, 26 | Escudero Lisa Ann | other | 1,547 |
| Aug 6, 26 | Bendheim Daniel M | other | 11,699 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PAHC coverage
Recent articles, reports, and earnings notes.

Phibro Animal Health (PAHC): Growth vs. Leverage Risk
Phibro Animal Health is executing well after the Zoetis portfolio acquisition, with double-digit sales and EBITDA growth. But elevated leverage and regulatory exposure keep the stock in Hold territory.

Phibro Animal Health Corporation (PAHC) gains on deep earnings
Phibro Animal Health Corporation (PAHC) gained after a strong earnings beat, but the bigger story is the depth behind it: profit growth outpaced revenue, Animal Health led segment momentum, and management raised fiscal 2026 and 2027 guidance above consensus, reinforcing the bullish setup.

Phibro Animal Health Corporation (PAHC) rises on earnings beats
Phibro Animal Health Corporation (PAHC) rises 6.2% after posting earnings beats, lifting shares as investors react to stronger-than-expected quarterly results.
Want a deeper read on PAHC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Phibro Animal Health Corporation (PAHC) Q1 2027 Earnings Call Transcript
seekingalpha.com · Nov 7
Phibro (PAHC) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com · Nov 4
Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance
businesswire.com · Nov 4
Phibro Animal Health Corporation Declares Quarterly Dividend
businesswire.com · Nov 3
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
businesswire.com · Oct 28
Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
zacks.com · Oct 23
PAHC or SYK: Which Is the Better Value Stock Right Now?
zacks.com · Oct 21
PAHC vs. HAE: Which Stock Is the Better Value Option?
zacks.com · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice